In recent trading, shares of Quest Diagnostics, Inc. (Symbol: DGX) have crossed above the average analyst 12-month target price of $159.00, changing hands for $160.14/share. When a stock reaches the ...
The average one-year price target for Co-Diagnostics (NasdaqCM:CODX) has been revised to $38.25 / share. This is an increase of 2,900.00% from the prior estimate of $1.28 dated December 18, 2025. The ...
CEO Lishan Aklog highlighted a strong close to 2024 and an optimistic start to 2025, driven by advancements in EsoGuard sales channels, reimbursement milestones, and increased clinical evidence. He ...
CEO Dwight Egan highlighted the development advancements of the Co-Dx PCR testing platform, including its low-cost, rapid, and easy-to-use features. The company withdrew its initial FDA 510(k) ...
Investing.com - Ascendiant Capital has raised its price target on Lucid Diagnostics Inc (NASDAQ:LUCD) to $8.25 from $8.00 while maintaining a Buy rating on the stock. This target represents a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results